In addition to drug products based on our proprietary delivery technology, we have a portfolio of generic product candidates with favorable commercial agreements that supplement our branded pipeline.

In Market

acyclovir cream, 5%
(RLD: ZOVIRAX®)

Sales as of
January 2019

Pending

ivermectin cream, 1%
(RLD: SOOLANTRA®)

Tentative Approval
as of January 2019

5-fluorouracil cream, 5%
(RLD: EFUDEX®)

Bioequivalence
Study Completed

Additional R&D

In addition to advancing our lead product candidates, we are also engaged in the formulation and pre-clinical development of early-stage innovative product candidates for both current indications, such as acne and rosacea, and for other dermatological indications.


All trademarks are the properties of their prospective owners.